With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
India's cheap weight-loss drugs could reshape global obesity fight
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
